Clinical trials: Head and Neck Cancers- Squamous Cell
Head and Neck Cancer, Squamous Cell Cancer
Zalutumumab in Non-curable Patients With SCCHN
Treatment, In combination with BSC, Open-label, Single arm, Efficacy Study.
- Trial name
- NCT00542308
- Testing
- Zalutumumab
- Where
- 48 sites in United States, Austria and 9 more
- Volunteers
- 90 people
- Sponsor
- Genmab
Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Cancer, Squamous Cell
MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell Carcinoma
SUMMARY Rationale: Esophageal cancer (EC) is the seventh most frequently diagnosed cancer and the sixth leading cause of cancer-related death worldwide.
- Trial name
- ESCALATE (NCT07359417)
- Testing
- Radiation: MRI guided radiotherapy
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- UMC Utrecht
Squamous Cell Carcinoma of the Head and Neck
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
The primary objective of the study was to demonstrate superior efficacy of Xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
- Trial name
- NCT04459715
- Testing
- Xevinapant (Debio 1143), Cisplatin, Intensity Modulation Radiation Therapy (IMRT)
- Where
- 288 sites in United States, Argentina and 24 more
- Volunteers
- 730 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
The purpose of this study is to assess the safety and determine MTD (maximal tolerated doses) and recommended doses of neoadjuvant sorafenib (BAY 43-9006) and concurrent sorafenib, cisplatin and radiation in the locally advanced…
- Trial name
- NCT00627835
- Testing
- sorafenib, sorafenib and cisplatin
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Head and Neck Cancer, Squamous Cell Cancer
Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
This study seeks to develop a new induction chemotherapy regimen which is a combination of two pill drugs taken by mouth and two drugs given by vein.
- Trial name
- NCT01721525
- Testing
- Afatinib, Ribavirin, and weekly carboplatin/paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glottis Tumor, Larynx Cancer
VoiceS: Voice Quality After Transoral CO2-Laser Surgery Versus Single Vocal Cord Irradiation for Larynx Cancer
Laser surgery and radiotherapy are well-established standards of care for unilateral stage 0 \& I carcinoma in situ (Cais) and squamous cell carcinoma of glottic larynx (SCCGL).
- Trial name
- VoiceS (NCT04057209)
- Testing
- Single Vocal Cord Irradiation (SVCI), Arm A: Transoral CO2-Laser Microsurgical Cordectomy (TLM)
- Where
- 4 sites in France, India and 1 more
- Volunteers
- 34 people
- Sponsor
- Olgun Elicin
Head and Neck Squamous Cell Carcinoma (HNSCC)
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
The purpose of this study is to determine the false negative rate (FNR) associated with Lymphoseek-identified sentinel lymph nodes (SLNs) relative to the pathological status of non-sentinel lymph nodes in elective neck dissection…
- Trial name
- NCT00911326
- Testing
- Lymphoseek
- Where
- 13 sites in United States
- Volunteers
- 101 people
- Sponsor
- Navidea Biopharmaceuticals
Biliary Tract Neoplasms, Gastric Cancer
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
This a prospective real-world navigation study using tumor DNA sequencing technology to sequence genes of previously treated and refractory gastrointestinal tumors, which are generally considered to be highly heterogeneous and…
- Conditions
- Biliary Tract Neoplasms, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- VISIONARY (NCT04584008)
- Testing
- FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al., Other Therapy
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Peking University
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
This Phase 1 study will evaluate the safety and tolerability of [Ga-68]-PNT6555 and [Lu-177]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin)
- Trial name
- NCT05432193
- Testing
- [Ga-68]-PNT6555, [Lu-177]-PNT6555
- Where
- 4 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Head and Neck Cancer
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
RATIONALE: SU5416 may stop the growth of head and neck cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005647
- Testing
- paclitaxel, semaxanib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Case Comprehensive Cancer Center
Oropharyngeal Cancers, Biomarker in Early Diagnosis
Active MMP-8 in Oral Fluid for the Detection of Oral and Oropharyngeal Cancer
The goal of this observational study is to evaluate whether the active-matrix metalloproteinase-8 (aMMP-8) mouth-rinse test can help detect oral and oropharyngeal cancers.
- Conditions
- Oropharyngeal Cancers, Biomarker in Early Diagnosis, Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity Cancer, Periodontal Diseases
- Trial name
- NCT06701058
- Where
- Finland
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Head and Neck Cancer Squamous Cell Carcinoma
Immunotherapy and Nodal-Sparing Irradiation for T-Cell Induction and Unmasking of Tumor Antigenicity in the Microenvironment for Head and Neck Cancer
This is a non-comparative randomized Phase 2 study using the INITIUM regimen with or without elective nodal irradiation (ENI) delivered before surgery for resectable head and neck squamous cell carcinoma (HNSCC).
- Trial name
- INITIUM (NCT07773987)
- Testing
- Pembrolizumab, Radiotherapy, ENI
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical College of Wisconsin
Esophageal Cancer
A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to observe and evaluate the efficacy and safety of multiple drug combinations in the treatment of advanced esophageal squamous cell carcinoma.
- Trial name
- NCT03736863
- Testing
- Apatinib+ SHR-1210（Camrelizumab）, Apatinib+ SHR-1316（Adebrelimab）, SHR-1316（Adebrelimab）+SHR-A2009
- Where
- China
- Volunteers
- 147 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Esophageal Carcinoma, Neoadjuvant Therapy
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
The purpose of this study is to explore the effectiveness and safety of the combination of Anlotinib, Toripalimab, and albumin-bound paclitaxel with cisplatin for neoadjuvant therapy in resectable esophageal squamous cell…
- Trial name
- NCT05996484
- Testing
- Toripalimab, Anlotinib hydrochloride, Albumin paclitaxel
- Volunteers
- 25 people
- Sponsor
- Nanfang Hospital, Southern Medical University
cN0 Oral Squamous Cell Carcinomas
One-step Nucleic Acid Amplification for Detecting Lymph Node Metastasis of Head and Neck Squamous Cell Carcinoma
The investigators main objective is to show that OSNA technique is as accurate as pathological analysis (frozen section / HE staining and immunochemistry) to detect occult lymph node metastasis (micro and macrometastasis).
- Trial name
- OSNA-ORL (NCT02852343)
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Rennes University Hospital
Esophageal Squamous Cell Carcinoma, Tislelizumab
Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC
This is a single institution and single-arm phase I/II study to assess the feasibility and efficacy of tislelizumab plus chemoradiation for conversion therapy of patients with locally nonresectable ESCC.
- Conditions
- Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation
- Trial name
- LATE (NCT05394415)
- Testing
- Tislelizumab, Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Squamous Cell Head and Neck Carcinoma
Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux.
The purpose of this study is to demonstrate that induction chemotherapy followed by radiation therapy plus Cetuximab will give better results than the validated treatment (chemoradiotherapy), for treatment of locoregional…
- Trial name
- 2007/02 (NCT01233843)
- Testing
- carboplatin, 5 fluorouracil, radiation therapy
- Where
- France
- Volunteers
- 370 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Esophageal Adenocarcinoma, Esophagus SCC
Multiorgan Metabolic Imaging Response Assessment of Abemaciclib
Open-label, phase II, basket trial. This trial is a screening program for abemaciclib efficacy in multiple platinum-resistant tumour types by using metabolic imaging (PERCIST) and RECIST v1.1 criteria.
- Conditions
- Esophageal Adenocarcinoma, Esophagus SCC, Cholangiocarcinoma, Urothelial/Bladder Cancer, Nos
- Trial name
- MiMe-A (NCT03339843)
- Testing
- Abemaciclib
- Where
- 11 sites in Belgium, France
- Volunteers
- 85 people
- Sponsor
- Jules Bordet Institute
Primary Advanced Carcinoma of the Oral Cavity or Oropharynx, Squamous Cell Carcinoma of the Head and Neck
Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor
The primary goal of this study is to determine if the vaccine can be safely given to subjects, and to see what side effects occur (both good and bad) when they are given this experimental tumor vaccine.
- Trial name
- NCT00377247
- Testing
- autologous monocyte-derived dendritic cells (DC) transfected with DNA
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pittsburgh
Squamous Cell Carcinoma of Head and Neck
Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma
This study is a prospective open label, multicenter, phase II, window-of-opportunity preoperative, single-agent trial. This study aims to evaluate the efficacy, the safety and tolerability profile of bintrafusp alfa in patients…
- Trial name
- ICING (NCT04428047)
- Testing
- bintrafusp alfa
- Where
- 8 sites in France
- Volunteers
- 7 people
- Sponsor
- UNICANCER
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.